(Q30240175)

12 June 2017

1 reference

title

Investigational hemagglutinin-targeted influenza virus inhibitors (English)

1 reference

12 June 2017

3

Shuwen Liu

1 reference

12 June 2017

2

Jie Yang

1 reference

12 June 2017

Li-Yan Zeng

1

1 reference

12 June 2017

language of work or name

English

0 references

publication date

5 December 2016

1 reference

Expert Opinion on Investigational Drugs

12 June 2017

published in

1 reference

12 June 2017

volume

26

1 reference

12 June 2017

issue

1

1 reference

12 June 2017

page(s)

63-73

1 reference

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

12 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Burden of paediatric influenza in Western Europe: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Antiviral combinations for severe influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Effectiveness of influenza vaccine in the community-dwelling elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Oseltamivir resistance during treatment of influenza A (H5N1) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Avian flu: isolation of drug-resistant H5N1 virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

A review of neuraminidase inhibitor susceptibility in influenza strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Antiviral agents active against influenza A viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Patterns of evolution and host gene mimicry in influenza and other RNA viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Phylogenetic properties of RNA viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Evolutionary history and phylodynamics of influenza A and B neuraminidase (NA) genes inferred from large-scale sequence analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

New world bats harbor diverse influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Insight into structural diversity of influenza virus haemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

'Flu' and structure-based drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Receptor binding by a ferret-transmissible H5 avian influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Inhibitors targeting the influenza virus hemagglutinin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Influenza A virus entry inhibitors targeting the hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Learning from structure-based drug design and new antivirals targeting the ribonucleoprotein complex for the treatment of influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Computational Design of Proteins Targeting the Conserved Stem Region of Influenza Hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Arbidol as a broad-spectrum antiviral: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Arbidol: a broad-spectrum antiviral compound that blocks viral fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Inhibition of influenza hemagglutinin with the antiviral inhibitor arbidol using a proteomics based approach and mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Design of inhibitors of influenza virus membrane fusion: synthesis, structure-activity relationship and in vitro antiviral activity of a novel indole series

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Antibody recognition of a highly conserved influenza virus epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

A highly conserved neutralizing epitope on group 2 influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

A broadly neutralizing human monoclonal antibody is effective against H7N9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Influenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Characterization of a hemagglutinin-specific inhibitor of influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Development of anti-influenza virus drugs I: improvement of oral absorption and in vivo anti-influenza activity of Stachyflin and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Identification of a novel HA conformational change inhibitor of human influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Identification of amino acids of influenza virus HA responsible for resistance to a fusion inhibitor, Stachyflin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Theoretical studies of the interaction between influenza virus hemagglutinin and its small molecule ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Structure-activity relationships of 3-O-β-chacotriosyl ursolic acid derivatives as novel H5N1 entry inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Nitazoxanide: a first-in-class broad-spectrum antiviral agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Analyzing the relationship of QT interval and exposure to nitazoxanide, a prospective candidate for influenza antiviral therapy--A formal TQT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Design and synthesis of benzenesulfonamide derivatives as potent anti-influenza hemagglutinin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Inhibition of influenza A virus (H1N1) fusion by benzenesulfonamide derivatives targeting viral hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Influenza neuraminidase: a druggable target for natural products

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Natural Products as Promising Therapeutics for Treatment of Influenza Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Antiviral effect of catechins in green tea on influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Total synthesis of (+)-stachyflin: a potential anti-influenza A virus agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Discovery of pentacyclic triterpenoids as potential entry inhibitors of influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

The use of sialidase therapy for respiratory viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

A "building block" approach to the new influenza A virus entry inhibitors with reduced cellular toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

New influenza A Virus Entry Inhibitors Derived from the Viral Fusion Peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Super short membrane-active lipopeptides inhibiting the entry of influenza A virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Pandemic influenza: a potential role for statins in treatment and prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Treating influenza with statins and other immunomodulatory agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Virological clearance rate of high-dose oseltamivir or triple-combination antiviral therapy in complicated 2009 pandemic influenza A (H1N1) infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Combination therapy with hepatocyte growth factor and oseltamivir confers enhanced protection against influenza viral pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1269170

10.1080/13543784.2017.1269170

21 January 2018

Identifiers

DOI

1 reference

12 June 2017

1 reference